Evaluating Fair Market Value
in Manufacturer-Physician Consulting Arrangements
Fair market value (FMV) in manufacturer-physician consulting arrangements is governed by a defined legal framework and remains a central focus of regulatory scrutiny. This analysis examines the legal framework governing FMV, reviews government enforcement activity targeting physician consulting arrangements, and outlines key considerations for developing a defensible approach.
Why This Analysis Matters
Manufacturer–physician consulting arrangements implicate the federal Anti-Kickback Statute and the False Claims Act. The Anti-Kickback Statute criminalizes payments made in whole or in part to induce sales, while the False Claims Act addresses fraudulent claims submitted to government programs. Consulting arrangements with fees that appear in excess of FMV can trigger alleged violations of both statutes.
Statutory safe harbors, such as the personal services contract exception, can shelter companies from Anti-Kickback Statute claims, but claiming a safe harbor requires more than asserting that compensation was set at FMV. Companies must also demonstrate a consistently applied, well-formulated, and documented FMV payment methodology. The absence of such documentation leaves companies exposed to criminal, civil, and administrative enforcement actions.
The stakes are not abstract. Two landmark settlements illustrate the government's focus on this area: Medtronic, Inc. paid $40 million in 2006, and five orthopedic device manufacturers paid a combined $311 million in 2007 to resolve Anti-Kickback Statute and False Claims Act allegations. Both actions centered specifically on physician consulting arrangements for services that appeared to exceed FMV. These cases represent the first major cases on physician contracting and provide insight into what government prosecutors will prioritize going forward.
Government scrutiny has intensified for several reasons, including negative media coverage, congressional oversight, administrative rulings, and costly court settlements. Corporate Integrity Agreements arising from these settlements have increasingly focused on FMV compensation, requiring companies to maintain arrangement databases, implement written approval processes, and in some cases engage independent third-party reviewers.
Core Considerations in FMV Analysis
The Arm’s-Length Standard and Its Practical Challenges
The arm’s-length transaction between unrelated parties is the foundational objective of FMV, consistent with the IRS definition of FMV as the price at which property would change hands between a willing buyer and a willing seller, neither under compulsion and both having knowledge of relevant facts. In the healthcare context, however, pharmaceutical and medical device companies are not fully independent of the physicians they engage, because those same physicians may refer or prescribe the company’s products.
This intertwined relationship creates a potential bias that could inflate compensation above FMV and complicates reliance on observed transactions between these parties as a basis for determining FMV.Flaws in Commonly Used Data Sources
Three data sources have historically been used to set fee schedules, each of which presents potential limitations or bias. The first is a company's own historical payment patterns. While this approach may be well-intentioned, it is not an independent measure of FMV because it reflects only a single company’s payment history, ignores all payments between physicians and other companies or institutions, and may have been inflated over time through the intertwined relationship between the physician and the company.
The second is industry benchmarks—typically formal third-party surveys of payment practices within the pharmaceutical and medical device industries, or informal understandings of competitor practices. These data may also be a tainted source for similar reasons: because it can be difficult to prove that benchmarked payments were made solely for the specific consulting services provided, regulators may argue that industry-wide internal standards have been inflated.
The third is HCP-requested amounts, which may reflect suggestions from meeting planning companies, feedback from market research vendors, or individual requests. These vendors are paid by the pharmaceutical or device company as pass-through costs, which may reduce their incentive to negotiate fees down to FMV. Taken together, these approaches do not provide an independent or unbiased measure of fair market value.Physician Compensation Surveys as an Alternative Foundation
A more defensible approach is to ground FMV hourly rates in national physician compensation surveys provided by independent third-party institutions. Unlike industry benchmarks, these surveys examine annual compensation paid to physicians by their employers—hospitals, group practices, and similar institutions—and are therefore viewed as reflecting arm’s-length transactions between physicians and entities that have no conflicting interest in their prescribing or referring behavior. Use of such surveys is supported by analogous data used in regulatory analysis.
Paying for Time, Not for the Category of Service
FMV should distinguish between compensating an HCP for the value of his or her time and compensating based on the perceived value of the services to the company. Payments should be based on reasonably compensating the HCP for time, and should not vary based on the category of activity or the value the company gains from the engagement. A physician attending a one-day advisory board to review marketing materials should receive the same fee as one attending a one-day advisory board to identify research priorities, because the time involved is identical.
Differentiated Payments Grounded in Expertise
FMV data must support differentiated payments between physicians with different levels of expertise. Many companies provide different fees for local, regional, national, and global thought leaders, and differentiation may also reflect physician specialty and licensure. Premiums for expertise must be supported by objective data and correspond to higher levels of experience or specialization.
Documentation and Consistent Application
Documentation and consistent application are essential to a defensible FMV methodology. Well-documented standards allow companies to demonstrate that their FMV rates are based on unbiased market values and applied consistently in the contracting process and in practice. Inconsistent application will cause regulators to question what other factors influenced rate selection. While FMV methodologies may provide some latitude in the specific rates chosen, once established those rates must be applied consistently.
Arrangements Involving Unique Skill Sets
Most FMV methodologies apply to the majority of physician contracts but may not hold in situations involving unique or highly specialized expertise, where a true market price rarely exists due to the absence of multiple buyers and sellers of the relevant expertise. In these cases, companies must demonstrate that they engaged in a genuine negotiation with the service provider.
Business Need as a Required Element
A clear and legitimate business need is a required element of defensible consulting arrangements. The absence of such a need raises significant concern regarding Anti-Kickback Statute exposure and may call into question the purpose of the engagement. This is a critical element and is often overlooked.
A Defensible Approach to FMV
Establishing fair market value in manufacturer–physician consulting arrangements requires more than reference to observed payment practices. Common inputs such as internal payment history, industry benchmarks, and requested rates do not provide an independent basis for determining FMV.
A defensible approach requires grounding compensation in objective measures of physician earnings, applying rates consistently, and ensuring that payments reflect time and expertise rather than the perceived value of the engagement. Where these elements are not present, compensation decisions become more difficult to support and may be subject to regulatory scrutiny. Where they are applied in a structured and consistent manner, they provide a more reliable foundation for evaluating FMV.
About This Publication
This article is based on prior published work in the Food and Drug Law Journal, a peer-reviewed law journal focused on healthcare and FDA-regulated industries.
To request a copy of the original publication, please use the button below.